Ultragenyx Pharmaceutical (NASDAQ:RARE) EVP Karah Herdman Parschauer Sells 8,135 Shares

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) EVP Karah Herdman Parschauer sold 8,135 shares of Ultragenyx Pharmaceutical stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $22.80, for a total value of $185,478.00. Following the completion of the transaction, the executive vice president directly owned 76,346 shares of the company’s stock, valued at approximately $1,740,688.80. This represents a 9.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Ultragenyx Pharmaceutical Stock Performance

NASDAQ RARE opened at $22.07 on Wednesday. Ultragenyx Pharmaceutical Inc. has a one year low of $18.41 and a one year high of $42.37. The firm has a 50 day simple moving average of $23.82 and a 200-day simple moving average of $29.24. The firm has a market cap of $2.13 billion, a price-to-earnings ratio of -3.78 and a beta of 0.16.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.09). Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 85.54%.The business had revenue of $207.28 million for the quarter, compared to analyst estimates of $199.60 million. During the same quarter last year, the company earned ($1.39) earnings per share. Ultragenyx Pharmaceutical’s quarterly revenue was up 25.5% compared to the same quarter last year. Equities analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Ultragenyx Pharmaceutical News Summary

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Neutral Sentiment: Management presentation transcript from TD Cowen’s 46th Annual Health Care Conference is available; this is informational for modeling product timelines and pipeline commentary but contains no new regulatory decisions. TD Cowen Presentation Transcript
• Negative Sentiment: Large, concentrated insider selling by multiple senior executives (CEO Emil Kakkis sold 54,404 shares; several EVPs, the CFO and CAO also sold material blocks) — these trades reduced several insiders’ holdings by ~3–10% and totaled well over $1M for the CEO alone. Such coordinated/large insider liquidity can signal personal cash needs or tax planning, but markets often read it as a negative signal for near-term sentiment. SEC filing (CEO sale) here: Insider Sale SEC Filing
• Negative Sentiment: Multiple law firms have announced or are soliciting lead plaintiffs for a securities-fraud class action (alleging misstatements/omissions related to setrusumab) covering Aug 3, 2023–Dec 26, 2025; several firms set April 6 lead‑plaintiff deadlines. The proliferation of notices and a filed class action increases legal and financial uncertainty and is likely exerting downward pressure on the stock. Example notice: Kessler Topaz Class Action Notice

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Norges Bank acquired a new stake in Ultragenyx Pharmaceutical during the second quarter worth approximately $35,765,000. Hsbc Holdings PLC grew its position in shares of Ultragenyx Pharmaceutical by 88.6% in the 2nd quarter. Hsbc Holdings PLC now owns 97,197 shares of the biopharmaceutical company’s stock valued at $3,554,000 after buying an additional 45,665 shares during the last quarter. Skandinaviska Enskilda Banken AB publ raised its stake in Ultragenyx Pharmaceutical by 108.1% during the 2nd quarter. Skandinaviska Enskilda Banken AB publ now owns 67,720 shares of the biopharmaceutical company’s stock worth $2,462,000 after acquiring an additional 35,185 shares in the last quarter. Frazier Life Sciences Management L.P. raised its stake in Ultragenyx Pharmaceutical by 49.3% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 983,715 shares of the biopharmaceutical company’s stock worth $35,768,000 after acquiring an additional 325,000 shares in the last quarter. Finally, Schroder Investment Management Group lifted its position in Ultragenyx Pharmaceutical by 27.2% in the second quarter. Schroder Investment Management Group now owns 336,173 shares of the biopharmaceutical company’s stock valued at $12,223,000 after acquiring an additional 71,888 shares during the last quarter. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on RARE. Leerink Partners lowered their target price on Ultragenyx Pharmaceutical from $80.00 to $70.00 and set an “outperform” rating for the company in a research note on Tuesday, December 30th. Jefferies Financial Group reduced their price target on Ultragenyx Pharmaceutical from $114.00 to $63.00 and set a “buy” rating on the stock in a research report on Tuesday, December 30th. Truist Financial lowered their price objective on Ultragenyx Pharmaceutical from $100.00 to $90.00 and set a “buy” rating for the company in a research report on Wednesday, November 5th. Wells Fargo & Company cut their target price on shares of Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an “overweight” rating on the stock in a research note on Tuesday, December 30th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, January 21st. Sixteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $68.29.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.